Bio Medica LaboratoriesNSE:BMLL +0.49%14 ROA % is 33.40% as of Mar. 2025, which is 148% above its 10-year median of 13.47. GuruFocus rates NSE:BMLL with a GF Score™ of 14/100. The stock has 2 warning signs investors should review. Among 857 Medical Devices & Instruments companies, Bio Medica Laboratories ranks better than 98.83% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Bio Medica Laboratories's annualizedNet Income for the quarter that ended in Mar. 2025 was ₹97.9 Mil.
Bio Medica Laboratories's average Total Assets over the quarter that ended in Mar. 2025 was ₹293.2 Mil. Therefore, Bio Medica Laboratories's annualized ROA % for the quarter that ended in Mar. 2025 was 33.40%.
The historical rank and industry rank for Bio Medica Laboratories's ROA % or its related term are showing as below:
NSE:BMLL'
s ROA % Range Over the Past 10 Years
Min: 1.9 Med: 13.47 Max: 33.4
Current: 33.4
During the past 3 years, Bio Medica Laboratories's highest ROA % was 33.40%. The lowest was 1.90%. And the median was 13.47%.
NSE:BMLL's ROA % is ranked better than 98.83% of 857
companies
in the Medical Devices & Instruments industry
Industry Median: 0.54
vs NSE:BMLL: 33.40
Bio Medica Laboratories (NSE:BMLL) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is one times the annual (Mar. 2025) net income data. The Revenue data used here is one times the annual (Mar. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio Medica Laboratories ROA % Chart
Bio Medica Laboratories Annual Data
Trend
Mar23
Mar24
Mar25
ROA %
1.90
13.47
33.40
Bio Medica Laboratories Semi-Annual Data
Mar23
Mar24
Mar25
ROA %
1.90
13.47
33.40
NSE:BMLL vs ISRG, BDX, MDLN: ROA % Comparison
For the Medical Instruments & Supplies subindustry, Bio Medica Laboratories's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio Medica Laboratories ROA % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio Medica Laboratories's ROA % distribution charts can be found below:
* The bar in red indicates where Bio Medica Laboratories's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is one times the annual (Mar. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Bio Medica Laboratories (NSE:BMLL) has a ROA % of 33.40% as of Mar. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Bio Medica Laboratories and its competitors. This is 148% above median its historical median of 13.47. Over the past decade, Bio Medica Laboratories' ROA % has ranged from 1.90 to 33.40. According to the industry distribution chart, Bio Medica Laboratories ranks #10 out of 857 companies in the Medical Devices & Instruments industry, placing it in the top 1.2%.
Is Bio Medica Laboratories' ROA % too high?
Bio Medica Laboratories' current ROA % of 33.40% is 148% above median its 10-year median of 13.47. Over the past 10 years, this metric has ranged from a low of 1.90 to a high of 33.40. The Medical Devices & Instruments industry median ROA % is 0.54. Bio Medica Laboratories' value of 33.40% is 6085.2% above this industry median. Based on the distribution chart, Bio Medica Laboratories ranks #10 out of 857 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bio Medica Laboratories has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Bio Medica Laboratories' ROA % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bio Medica Laboratories ranks #10 out of 857 companies for ROA %. This places Bio Medica Laboratories in the top 1% of its industry — outperforming the majority of peers. The industry median ROA % is 0.54. Bio Medica Laboratories' value of 33.40% is 6085.2% above this benchmark. Historically, Bio Medica Laboratories' own ROA % has ranged from 1.90 to 33.40 over the past decade. While the company's 10-year median is 13.47 vs. the industry median of 0.54, Bio Medica Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Devices & Instruments company?
The median ROA % among Medical Devices & Instruments companies is 0.54, based on 857 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio Medica Laboratories's current ROA % of 33.40% is 6085.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Bio Medica Laboratories and its competitors. For the Medical Devices & Instruments industry, the median ROA % is 0.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio Medica Laboratories's current ROA % is 33.40%, which is 148% above median its own 10-year median of 13.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio Medica Laboratories stock overvalued right now?
Bio Medica Laboratories (NSE:BMLL) has a current ROA % of 33.40%. The current ROA % is 33.40%, which is 148% above median its 10-year median of 13.47 and 6085.2% above the Medical Devices & Instruments industry median of 0.54. Bio Medica Laboratories' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Bio Medica Laboratories (NSE:BMLL), the current ROA % is 33.40% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bio Medica Laboratories Ltd is engaged in the manufacturing of Pharmaceutical Parenteral Formulations. It manufactures generic drugs in the form of injectables namely Liquid Injections and Dry Powder Injections. These injectables are available in both single dose and multi dose forms, catering both human and veterinary needs. Its products address a wide range of medical needs and preferences. The majority of revenue is derived from the sales of Liquid injections. Geographically, it operates predominantly in India, and internationally, it exports to Afghanistan.
14GF Score
Get the complete analysis for NSE:BMLL
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BMLL has been successfully added to your 